vs
ICU MEDICAL INC（ICUI）与RAYONIER ADVANCED MATERIALS INC.（RYAM）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是RAYONIER ADVANCED MATERIALS INC.的1.3倍（$540.7M vs $417.5M），ICU MEDICAL INC净利率更高（-2.9% vs -5.0%，领先2.1%），RAYONIER ADVANCED MATERIALS INC.同比增速更快（-1.2% vs -14.1%），过去两年RAYONIER ADVANCED MATERIALS INC.的营收复合增速更高（3.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
RYAM（原雷尼尔先进材料公司）是一家美国全球性纤维素技术企业，主打高纯度特种纤维素产品，所生产的天然聚合物广泛应用于过滤器生产、食品加工、医药制造及各类工业领域，同时也为造纸和包装行业供应相关产品，在纤维素技术领域拥有较高的行业认可度。
ICUI vs RYAM — 直观对比
营收规模更大
ICUI
是对方的1.3倍
$417.5M
营收增速更快
RYAM
高出13.0%
-14.1%
净利率更高
ICUI
高出2.1%
-5.0%
两年增速更快
RYAM
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $417.5M |
| 净利润 | $-15.7M | $-21.1M |
| 毛利率 | 37.5% | 8.9% |
| 营业利润率 | 1.0% | 2.6% |
| 净利率 | -2.9% | -5.0% |
| 营收同比 | -14.1% | -1.2% |
| 净利润同比 | 34.0% | -31.9% |
| 每股收益（稀释后） | $-0.63 | $-0.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRYAM
| Q4 25 | $540.7M | $417.5M | ||
| Q3 25 | $537.0M | $352.8M | ||
| Q2 25 | $548.9M | $340.0M | ||
| Q1 25 | $604.7M | $356.0M | ||
| Q4 24 | $629.8M | $422.5M | ||
| Q3 24 | $589.1M | $401.1M | ||
| Q2 24 | $596.5M | $419.0M | ||
| Q1 24 | $566.7M | $387.7M |
净利润ICUIRYAM
| Q4 25 | $-15.7M | $-21.1M | ||
| Q3 25 | $-3.4M | $-4.5M | ||
| Q2 25 | $35.3M | $-363.2M | ||
| Q1 25 | $-15.5M | $-32.0M | ||
| Q4 24 | $-23.8M | $-16.0M | ||
| Q3 24 | $-33.0M | $-32.6M | ||
| Q2 24 | $-21.4M | $11.4M | ||
| Q1 24 | $-39.5M | $-1.6M |
毛利率ICUIRYAM
| Q4 25 | 37.5% | 8.9% | ||
| Q3 25 | 37.4% | 9.7% | ||
| Q2 25 | 37.9% | 7.0% | ||
| Q1 25 | 34.7% | 6.8% | ||
| Q4 24 | 36.1% | 8.7% | ||
| Q3 24 | 34.8% | 10.9% | ||
| Q2 24 | 34.8% | 11.5% | ||
| Q1 24 | 32.7% | 9.5% |
营业利润率ICUIRYAM
| Q4 25 | 1.0% | 2.6% | ||
| Q3 25 | 2.6% | 2.8% | ||
| Q2 25 | 1.9% | -0.4% | ||
| Q1 25 | 2.1% | -4.2% | ||
| Q4 24 | 6.0% | 2.6% | ||
| Q3 24 | 1.4% | -4.2% | ||
| Q2 24 | 1.3% | 6.7% | ||
| Q1 24 | -1.9% | 4.4% |
净利率ICUIRYAM
| Q4 25 | -2.9% | -5.0% | ||
| Q3 25 | -0.6% | -1.3% | ||
| Q2 25 | 6.4% | -106.8% | ||
| Q1 25 | -2.6% | -9.0% | ||
| Q4 24 | -3.8% | -3.8% | ||
| Q3 24 | -5.6% | -8.1% | ||
| Q2 24 | -3.6% | 2.7% | ||
| Q1 24 | -7.0% | -0.4% |
每股收益（稀释后）ICUIRYAM
| Q4 25 | $-0.63 | $-0.33 | ||
| Q3 25 | $-0.14 | $-0.07 | ||
| Q2 25 | $1.43 | $-5.44 | ||
| Q1 25 | $-0.63 | $-0.49 | ||
| Q4 24 | $-0.97 | $-0.25 | ||
| Q3 24 | $-1.35 | $-0.49 | ||
| Q2 24 | $-0.88 | $0.17 | ||
| Q1 24 | $-1.63 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $75.4M |
| 总债务越低越好 | — | $758.1M |
| 股东权益账面价值 | $2.1B | $316.6M |
| 总资产 | $4.1B | $1.8B |
| 负债/权益比越低杠杆越低 | — | 2.39× |
8季度趋势，按日历期对齐
现金及短期投资ICUIRYAM
| Q4 25 | — | $75.4M | ||
| Q3 25 | — | $77.0M | ||
| Q2 25 | — | $70.7M | ||
| Q1 25 | — | $129.9M | ||
| Q4 24 | $308.6M | $125.2M | ||
| Q3 24 | $312.5M | $136.1M | ||
| Q2 24 | $302.6M | $114.1M | ||
| Q1 24 | $251.4M | $54.6M |
总债务ICUIRYAM
| Q4 25 | — | $758.1M | ||
| Q3 25 | — | $763.5M | ||
| Q2 25 | — | $720.4M | ||
| Q1 25 | — | $707.0M | ||
| Q4 24 | — | $706.4M | ||
| Q3 24 | — | $747.7M | ||
| Q2 24 | — | $752.8M | ||
| Q1 24 | — | $755.6M |
股东权益ICUIRYAM
| Q4 25 | $2.1B | $316.6M | ||
| Q3 25 | $2.1B | $338.2M | ||
| Q2 25 | $2.1B | $342.3M | ||
| Q1 25 | $2.0B | $688.1M | ||
| Q4 24 | $2.0B | $713.9M | ||
| Q3 24 | $2.0B | $732.7M | ||
| Q2 24 | $2.0B | $755.1M | ||
| Q1 24 | $2.1B | $741.8M |
总资产ICUIRYAM
| Q4 25 | $4.1B | $1.8B | ||
| Q3 25 | $4.1B | $1.8B | ||
| Q2 25 | $4.1B | $1.8B | ||
| Q1 25 | $4.2B | $2.1B | ||
| Q4 24 | $4.2B | $2.1B | ||
| Q3 24 | $4.3B | $2.2B | ||
| Q2 24 | $4.3B | $2.2B | ||
| Q1 24 | $4.3B | $2.1B |
负债/权益比ICUIRYAM
| Q4 25 | — | 2.39× | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | — | 2.10× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.02× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | — | 1.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $32.3M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIRYAM
| Q4 25 | $60.6M | $32.3M | ||
| Q3 25 | $56.7M | $-17.8M | ||
| Q2 25 | $11.2M | $-30.2M | ||
| Q1 25 | $51.3M | $39.6M | ||
| Q4 24 | $40.2M | $54.9M | ||
| Q3 24 | $36.1M | $49.8M | ||
| Q2 24 | $82.0M | $87.6M | ||
| Q1 24 | $45.8M | $11.3M |
自由现金流ICUIRYAM
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | — | ||
| Q1 24 | $29.9M | — |
自由现金流率ICUIRYAM
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.3% | — |
资本支出强度ICUIRYAM
| Q4 25 | 4.6% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 2.8% | — |
现金转化率ICUIRYAM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 7.69× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RYAM
| Cellulose Specialties | $249.6M | 60% |
| Other | $86.2M | 21% |
| Paperboard | $44.2M | 11% |
| High Yield Pulp | $28.3M | 7% |
| Biomaterials | $9.2M | 2% |
